Zoetis Inc. (ZTS)
About Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $9.5B
- Net income
- $2.7B
- Total assets
- $15.5B
- Market cap
- $33.3B
- Gross margin
- 71.8%
- Operating margin
- 35.5%
- Net margin
- 28.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $9.5B
- Cost of revenue
- $2.7B
- Gross profit
- $6.8B
- Operating expenses
- $3.4B
- Operating income
- $3.4B
- Income tax
- $687.0M
- Net income
- $2.7B
- EPS (basic)
- $6.03
- EPS (diluted)
- $6.02
Balance sheet
- Total assets
- $15.5B
- Current assets
- $6.8B
- Total liabilities
- $12.1B
- Current liabilities
- $2.2B
- Shareholders’ equity
- $3.3B
Cash flow
- Operating cash flow
- $2.9B
- Investing cash flow
- -$748.0M
- Financing cash flow
- -$1.9B
- Net cash flow
- $325.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $33.3B
- P/E ratio
- 12.7
- EPS (diluted)
- $6.02
- Dividend yield
- 2.77%
- Shares outstanding
- 435.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 1, 2013
Zoetis Inc. (ZTS) Stock Price
- Profitable — net income of $2.7B in FY2025.
- Revenue grew 22% from FY2021 to FY2025.
- Gross margin of 71.8%, net margin 28.2%.
- Trading 53% below its 52-week high.
- Pays a dividend yielding about 2.77% annually.
- Valued at a price-to-earnings (P/E) ratio of 12.7.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Zoetis Inc..
Write a review
News about Zoetis Inc.
News & sentiment via Polygon.io
Zoetis Inc.: frequently asked questions
Is Zoetis Inc. an American company?
Yes — Zoetis Inc. is an American company headquartered in Parsippany, New Jersey. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.
Where is Zoetis Inc. headquartered?
Zoetis Inc. is headquartered in Parsippany, New Jersey, United States.
Is Zoetis Inc. publicly traded?
Yes — Zoetis Inc. is a publicly traded company. Its stock trades under the ticker symbol ZTS on the NYSE.
What does Zoetis Inc. do?
Zoetis Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
